Level and temporal trend of perfluoroalkyl acids in Greenlandic Inuit

Manhai Long¹, Rossana Bossi² and Eva C. Bonefeld-Jørgensen¹*

¹Aarhus University, School of Public Health, Centre of Arctic Environmental Medicine, Aarhus, Denmark; ²Aarhus University, National Environmental Research Institute, Roskilde, Denmark

Objectives: Perfluoroalkyl acids (PFAAs) have been detected in human blood, breast milk and umbilical cord blood across the globe. PFAAs do accumulate in the marine food chain in Arctic regions. In Greenland, increasing PFAA concentrations were observed during 1982–2006 in ringed seals and polar bears. However, until now, no data have been reported for PFAAs in Greenlandic Inuit. This study assesses the level and temporal trend of serum PFAAs in Greenlandic Inuit.

Study design: Cross-sectional and temporal time trend survey.

Methods: Serum PFAA levels were determined in 284 Inuit from different Greenlandic districts using liquid chromatography-tandem mass spectrometry with electrospray ionization. The temporal time trend of serum PFAAs in Nuuk Inuit during 1998–2005 and the correlation between serum PFAAs and legacy persistent organic pollutants (POPs) were explored.

Results: Serum PFAA levels were higher in Nuuk Inuit than in non-Nuuk Inuit. Within the same district, higher PFAA levels were observed for males. An age-dependent, increasing trend of serum PFAA levels in the period from 1998–2005 was observed for Nuuk Inuit. For the pooled gender data, no significant association between PFAAs and legacy POPs was observed for Nuuk Inuit while for non-Nuuk Inuit this correlation was significant. No correlation between PFAAs and legacy POPs was found for male Inuit, whereas significant correlation was observed both for pooled female Inuit and for non-Nuuk Inuit females.

Conclusions: We suggest that sources other than seafood intake might contribute to the observed higher PFAA levels in Nuuk Inuit compared to the pooled non-Nuuk Inuit.

Keywords: Perfluoroalkyl acids (PFAAs); Greenlandic Inuit; persistent organic pollutants (POPs); time trend.

To access the supplementary material to this article please see Supplementary files under Article Tools online

Received: 1 February 2011; Revised: 17 May 2011; Accepted: 12 July 2011; Published: 19 March 2012¹

Poly- and perfluorinated compounds (PFCs) are a large group of chemicals employed in different industrial and commercial applications (1). Two groups of PFCs, the perfluoro-carboxylated acids (PFCAs) and perfluorosulfonated acids (PFSA), are together commonly referred to as perfluoroalkyl acids (PFAAs). These compounds have received attention in recent years as a novel group of persistent organic pollutants (POPs) (2,3). Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) are the 2 most studied PFAAs. Adverse outcomes of exposure to PFOS and PFOA have been reported in animal studies; these outcomes have included decreased serum cholesterol, hepatotoxicity, thyroid hormone alterations, developmental toxicity, immuno-toxicity, neurotoxic effects and tumorigenicity (3–5). For humans, positive associations were observed between PFOA serum levels and cholesterol, uric acid and liver enzymes (6). Due to their resistance against degradation in the environment, their bioaccumulation in the food chain, their global distribution and their adverse health potentials, a series of governmental regulations have been taken by North American (7) and European authorities (8) on the use and production of PFOS and PFOA. PFOS and its salts

¹Published 'ahead-of-print' 13 December 2011 (at www.ijch.fi) in accordance with previous publisher's routines.
have recently been added to Annex B of the Stockholm Convention on POPs (9).

PFAAs have been found in human blood, breast milk and livers (2) with half-lives of 4–10 years (10). The developing fetus is especially sensitive to exposure to PFAAs. PFOA and PFOS exposure during fetal development has inverse effects on birth weight and length, as well as on head and abdominal circumference (11,12). It has been reported that PFOA and PFOS exposure at general population levels can reduce female fecundity (13).

Biomonitoring studies have been carried out in almost all parts of the world in order to assess PFAA levels and temporal trends in the general population (2,14). During 1997–2006, European studies reported median serum and plasma concentrations of PFOS and PFOA ranging from 3.5 to 34.2 ng/ml and from 3.4 to 6.8 ng/ml, respectively (14). The average plasma levels of PFOS and PFOA in pregnant Danish women during 1996–2002 was 35.3 and 5.6 ng/mL, respectively (11), similar to most levels reported for Western populations during the same decade (15). Mean and median concentrations from North American populations appear to be slightly higher than European, Asian and Australian populations (14). As a consequence of U.S. EPA and European regulations, and of ceased production of PFOS-based products from the world’s formerly largest producer (3M), human serum levels of PFOS and PFOA have shown a decreasing trend in studies from the United States and Norway (10,16,17). However, an increasing trend has been reported in studies from Japan and China (18,19).

It is well known that the Indigenous populations in the Arctic are particularly exposed to legacy POPs, such as polychlorinated biphenyl (PCBs) and organochlorine pesticides, through the intake of marine mammals. Recent studies have indicated that the consumption of local traditional food among Indigenous populations in Greenland has decreased by about 25% over the last 30 years, and that these foods now make up only approximately 20% of the total dietary intake (20,21). Women generally consume less local traditional food than men (21). The Arctic Monitoring and Assessment Programme (AMAP) has in the past 20 years assessed the concentration of legacy POPs in the different parts of the circumpolar region, as well as their spatial distributions and temporal trends in the Indigenous populations (20,22). These studies indicate that Inuit populations in Greenland, Canada and Alaska continue to have high concentrations of the legacy POPs (22), although recent data show a slight decreasing trend in concentrations for some legacy POPs, such as 2,2-bis(p-chlorophenyl)-1,11-trichloroethane (DDT), PCBs and oxychlordane in some Arctic regions, including Greenland (20–23).

In addition to legacy POPs, emerging contaminants including PFAAs are currently being detected in humans from the Arctic regions (20,22). Unlike legacy POPs, the level of PFAAs in marine mammals from Greenland has continued to show an increase over the past few years (24,25). Very sparse data on PFAA levels in humans from Arctic regions are available (20,26–28). The largest study on PFAAs was performed in the Arctic Canada (26) and included a data set for PFOS serum concentrations from 883 Canadian Inuit adults from Nunavik. The other published studies on human levels of PFOS and/or PFOA in the Arctic are mainly based on small-sample data sets (sample size ≤25) and are often performed on maternal blood. At present, the level of PFAAs has not yet been investigated for the Indigenous population in Greenland.

In this paper we present the level of 10 different PFAAs in serum from 284 adult Inuit belonging to 10 different Greenlandic districts. Moreover, we present the correlation between serum PFAAs and legacy POPs, and the temporal trend of PFAAs covering the period 1998–2005 for the district of Nuuk.

Material and methods

The participants and sample collection

All participants were of Inuit descent, defined as having more than 2 grandparentss born in Greenland. The participants were randomly selected from 10 Greenlandic districts – Quannaq, Upernavik, Ummannaq, Qeqertasuq, Ilulissat, Sisimiut, Nuuk, Narssaq, Tasilaq and Ittoqqortoormiit – in the period from 1997–2006 (Fig. 1). Participants from Nuuk during 2000–2002 were randomly selected from a cross-sectional study assessing legacy POP exposure on osteoporosis-related ultrasound bone measurements in Greenlandic Inuit women (29), and the rest of the participants were randomly selected from projects in the human health program of the ongoing circumpolar AMAP (21,30,31). The participation rate was more than 80% (21,29–31). Venous blood samples and questionnaires about demographic and lifestyle factors were collected. The serum was prepared and frozen at −80°C for further measurement (21,29,30).

The proposed protocols of the studies were accepted by the Ethical Committee for Scientific Investigations in Greenland and all the participants gave written informed consent.

PFAAs analysis

The following compounds were analysed in serum samples: perfluorohexanoic acid (PFHxA), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnA), perfluoroheptanoic acid (PFHpA), perfluorotridecanoic acid (PFTrA), perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS) and perfluorooctane sulfonamide (PFOSA). The following compounds from Wellington Laboratories were used
as surrogate standards: $^{13}$C$_8$-PFOA, $^{13}$C$_4$-PFOS and $^{13}$C$_2$-PFDA.

The extraction method was based on ion pairing as described by Hansen et al. (32). Instrumental analysis was performed by liquid chromatography-tandem mass spectrometry (LC-MS-MS) with electrospray ionization (ESI). The analytical method used here is described in detail in Bossi et al. (25). Method performance was tested through participation in inter-laboratory comparison studies organized by the Institute Nationale de Santé Publique du Québec for AMAP (33). Satisfactory z-scores were obtained in the inter-laboratory comparison studies from our laboratory.

**Measurement of legacy POPs and fatty acids**

Serum concentration of PCB congeners CB99, CB101, CB105, CB118, CB128, CB138, CB153, CB156, CB170, CB180, CB183 and CB187, and organochlorine pesticides including chlordanes, p,p'-dichlorodiphenyldichloroethane (p,p'-DDE), p,p'-dichlorodiphenyltrichloroethane (p,p'-DDT), oxychlordane, hexachlorobenzene (HCB), beta-hexachlorocyclohexane (β-HCH), mirex and toxaphene were measured at the certified laboratory, Le Centre Toxicologie, in Sainte Foy, Quebec, Canada (21,23,29,30).

The fatty acid profiles were determined in plasma phospholipids at the Biology Department of the University of Guelph, Ontario, Canada (23,34). The ratio between n-3 polyunsaturated fatty acids and n-6 fatty acids is known to be a strong indicator of seafood intake and thus is a good indicator of the relative consumption of traditional food versus imported food (35).

**Statistical analysis**

The statistical analysis of the data was performed in SPSS 13.0 (SPSS Inc., Chicago, IL) with a significance level of
p < 0.05. Half of the detection limit values were used in case of concentrations below the detection limit. Based on the chemical structure, the analysed PFAAs were grouped in perfluorosulfonated acids (ΣPFSA) – as in, the sum of PFOS, PFHxS and PFOSA – and perfluorocarboxylated acids (ΣPFCA), which were made up of the sum of PFHpA, PFbFOA, PFNA, PFDa, PFUnA, PFDoA and PFTrA. The legacy POPs were grouped in the sum of PFHpA, PFOA, PFNa, PFDA, PFUnA, linear component, and a simple, 3-point running mean linear regression analysis was applied to describe the variation in the contaminant index values over time was used as the yearly contaminant index value. The total Annual geometric mean concentrations of PFAAs were regression-based analysis to detect temporal trends (37). Exploration of the Sea, a method that employs a robust, trend assessments by the International Council for the assessment of data were included in the analysis. The analyses of data and pooled data. After adjustment for age and n-3/n-6, this significance persisted (Table II). Nuuk Inuit had significantly higher PFAA levels than pooled non-Nuuk Inuit, both for the separate gender data and pooled data. After adjustment for age and n-3/n-6, this significance persisted (Table II).

As for PFAAs, the levels of legacy POPs were generally higher for Nuuk Inuit compared to non-Nuuk Inuit. For the pooled gender data, levels of ΣPCBs, Σpesticides and Σlegacy POPs for Nuuk Inuit were significantly higher than for pooled non-Nuuk Inuit (Table II). However, after adjustment for age and n-3/n-6, ΣPCB levels were not significantly different between the Nuuk district and pooled non-Nuuk district for the separate genders, whereas Σpesticides differed between the 2 district groups for both genders.

**Results**

**General characteristics of the study population**

Table I shows the characteristics of the study population. The median age of the Green-landic Inuit in the study was 50 years, ranged from 18 to 73 years. The included Inuit living in Nuuk were older than those living in the pooled non-Nuuk districts, in terms of both the separate genders and pooled gender data. It should be noted that data for only 5 males were included in the Nuuk district data. No significant difference was found in the BMI and the seafood intake biomarker (n-3/n-6) between Nuuk and non-Nuuk Inuit. Most participants (68.9%) were smokers, but no difference was observed between districts. No gender differences were observed for age, BMI, n-3/n-6 and smoking status within Nuuk and pooled non-Nuuk districts (p > 0.06) (Table I).

**District distribution of serum levels of PFAAs and legacy POPs**

PFAA concentrations differed significantly between the studied Inuit from Nuuk and pooled non-Nuuk districts. Nuuk Inuit had significantly higher PFAA levels than pooled non-Nuuk Inuit, both for the separate gender data and pooled data. After adjustment for age and n-3/n-6, this significance persisted (Table II). As for PFAAs, the levels of legacy POPs were generally higher for Nuuk Inuit compared to non-Nuuk Inuit. For the pooled gender data, levels of ΣPCBs, Σpesticides and Σlegacy POPs for Nuuk Inuit were significantly higher than for pooled non-Nuuk Inuit (Table II). However, after adjustment for age and n-3/n-6, ΣPCB levels were not significantly different between the Nuuk district and pooled non-Nuuk district for the separate genders, whereas Σpesticides differed between the 2 district groups for both genders.

**Gender differences in serum PFAA levels and legacy POP levels**

Serum PFAA levels in male Inuit were significantly higher than those in female Inuit both before and after adjustment for age and n-3/n-6 within both Nuuk and pooled non-Nuuk districts (Figure 2A, 2B). Significantly higher levels of Σlegacy POPs for males were found in the pooled non-Nuuk districts only, and a statistically insignificant tendency of higher legacy POPs in Nuuk males was observed, although the small sample
**Table 1.** Characteristics of Greenlandic Inuit participants

| Parameters          | Male | Female | p-value* | Male | Female | p-value* | Male | Female | p-value* |
|---------------------|------|--------|----------|------|--------|----------|------|--------|----------|
|                     | All  | Nuuk   | Non-Nuuk | All  | Nuuk   | Non-Nuuk | All  | Nuuk   | Non-Nuuk |
| Age (year)          |      |        |          |      |        |          |      |        |          |
| n                   | 74   | 5      | 69       | 190  | 127    | 63       | 264  | 132    | 132      |
| Median              |      |        |          |      |        |          |      |        |          |
|                  | 37.5 | 65.0   | 37.0     | 53.0 | 56.0   | 34.0     | 50.0 | 56.0   | 36.0     |
|                  | 18.0 | 43.0   | 18.0     | 18.0 | 34.0   | 18.0     | 18.0 | 34.0   | 18.0     |
|                  | 73.0 | 73.0   | 67.0     | 66.0 | 66.0   | 62.0     | 73.0 | 73.0   | 67.0     |
| p-value (m vs. f in Nuuk) | ns  |        |          |      |        |          |      |        |          |
| p-value (m vs. f in non-Nuuk) | ns  |        |          |      |        |          |      |        |          |
| BMI (kg/m²)         |      |        |          |      |        |          |      |        |          |
| n                   | 50   | 5      | 45       | 187  | 127    | 60       | 237  | 132    | 105      |
| Median              |      |        |          |      |        |          |      |        |          |
|                  | 26.4 | 24.9   | 27.0     | 25.8 | 25.9   | 25.1     | 25.9 | 25.9   | 25.4     |
|                  | 17.6 | 23.1   | 17.6     | 16.6 | 16.6   | 18.2     | 16.6 | 16.6   | 17.6     |
|                  | 37.0 | 26.1   | 37.0     | 43.4 | 43.4   | 37.5     | 43.4 | 43.4   | 37.5     |
| p-value (m vs. f in Nuuk) | ns  |        |          |      |        |          |      |        |          |
| p-value (m vs. f in non-Nuuk) | ns  |        |          |      |        |          |      |        |          |
| n-3/n-6             |      |        |          |      |        |          |      |        |          |
| n                   | 69   | 5      | 64       | 190  | 127    | 63       | 260  | 132    | 128      |
| Median              |      |        |          |      |        |          |      |        |          |
|                  | 0.3  | 0.5    | 0.3      | 0.5  | 0.6    | 0.4      | 0.4  | 0.6    | 0.3      |
|                  | 0.1  | 0.2    | 0.1      | 0.1  | 0.1    | 0.2      | 0.1  | 0.1    | 0.1      |
|                  | 1.5  | 1.2    | 1.5      | 2.2  | 2.2    | 1.4      | 2.2  | 2.2    | 1.5      |
| p-value (m vs. f in Nuuk) | ns  |        |          |      |        |          |      |        |          |
| p-value (m vs. f in non-Nuuk) | ns  |        |          |      |        |          |      |        |          |
| Smoking             |      |        |          |      |        |          |      |        |          |
| n                   | 74   | 5      | 69       | 190  | 127    | 63       | 264  | 132    | 132      |
| Yes (%)             |      |        |          |      |        |          |      |        |          |
|                  | 48 (64.9%) | 4 (80%)   | 44 (63.8%) | 134 (70.5%) | 91 (71.7%) | 43 (68.3%) | 182 (68.9%) | 95 (72%) | 87 (65.9%) |
| No (%)              |      |        |          |      |        |          |      |        |          |
|                  | 26 (35.1%) | 1 (20%)   | 25 (36.2%) | 56 (29.5%) | 36 (28.3%) | 20 (31.7%) | 82 (31.1%) | 37 (28%) | 45 (34.1%) |
| p-value (m vs. f in Nuuk) | ns  |        |          |      |        |          |      |        |          |
| p-value (m vs. f in non-Nuuk) | ns  |        |          |      |        |          |      |        |          |

*Nuuk vs. non-Nuuk; aadjusted for age. m = male, f = female. ns = not significant (p > 0.05).
| Parameters | Male | Female | Male + Female |
|------------|------|--------|----------------|
| PFOS (ng/ml) | n | 74 | 137 | 72 | 284 | 142 | 142 |
| Median | 14.9 | 19.5 | 14.8 | 18.5 | 29.9 | 12.2 |
| Min | 3.96 | 1.5 | 3.70 | 1.53 | 3.70 | 1.5 |
| Max | 213 | 172 | 103.0 | 213 | 213 | 103.0 |
| PFOA (ng/ml) | n | 74 | 137 | 72 | 284 | 142 | 142 |
| Median | 0.94 | 1.7 | 0.52 | 1.45 | 2.6 | 0.9 |
| Min | 0.20 | 0.2 | 0.36 | 0.20 | 0.20 | 0.4 |
| Max | 10.8 | 7.8 | 4.10 | 10.8 | 10.8 | 8.6 |
| PFSA (ng/ml) | n | 74 | 137 | 72 | 284 | 142 | 142 |
| Median | 16.6 | 23.1 | 11.6 | 21.6 | 32.7 | 13.6 |
| Min | 4.5 | 2.0 | 4.70 | 2.0 | 4.70 | 2.0 |
| Max | 229.0 | 184.0 | 90.1 | 229 | 229.0 | 113.0 |
| PFCA (ng/ml) | n | 74 | 137 | 72 | 284 | 142 | 142 |
| Median | 2.8 | 4.5 | 2.35 | 3.84 | 6.2 | 2.6 |
| Min | 1.3 | 1.0 | 1.63 | 0.96 | 1.63 | 1.0 |
| Max | 43.0 | 28.1 | 16.3 | 43.0 | 43.0 | 16.9 |
| PCBs (µg/kg lipid) | n | 74 | 137 | 72 | 284 | 142 | 142 |
| Median | 1630.5 | 1752.7 | 1015.1 | 1739.1 | 1995.2 | 1350.6 |
| Min | 201.6 | 92.7 | 92.7 | 92.7 | 207.8 | 92.7 |
| Max | 16827.5 | 11275.3 | 11275.3 | 16827.5 | 5640.2 | 16827.5 |
| Pesticides (µg/kg lipid) | n | 74 | 137 | 72 | 284 | 142 | 142 |
| Median | 2857.8 | 2664.0 | 1366.0 | 2666.6 | 2795.8 | 2123.7 |
| Min | 1433.9 | 92.5 | 92.5 | 92.5 | 175.3 | 92.5 |
| Max | 25681.1 | 10939.3 | 10939.3 | 25681.1 | 9284.8 | 15610.4 |
| Legacy POPs (µg/kg lipid) | n | 74 | 137 | 72 | 284 | 142 | 142 |
| Median | 5075.5 | 4433.4 | 2557.3 | 4433.9 | 4618.2 | 3627.1 |
| Min | 473.3 | 187.8 | 187.8 | 187.8 | 383.2 | 187.8 |
| Max | 25681.1 | 20073.3 | 20073.3 | 25681.1 | 13950.4 | 25681.1 |

* Nuuk vs. non-Nuuk; ( ) p-value of Nuuk vs. non-Nuuk after adjustment for age and n-3/n-6; § Legacy POPs is the summation of PCBs and pesticides (ΣPCBs + ΣPesticides). Two subjects from Upernavik district had relatively high values of PFAAs (PFOS: 91.8 and 74.9 ng/ml; PFOA: 8.6 and 4.0 ng/ml; ΣPFSA: 101 and 83.5 ng/ml; ΣPFCA: 12.8 and 9.85ng/ml). However, similar results were obtained upon including and excluding these 2 subjects. ns = not significant (p > 0.05).
size of Nuuk males must be taken into consideration (Figure 2C).

Correlation between serum lifestyle factors and PFAAs, legacy POPs

A significant but weakly positive correlation between age and serum PFAA levels \((r < 0.27, p < 0.05)\) was observed for both Nuuk and non-Nuuk Inuit (Supplementary Table I a, www.ijch.fi). Legacy POPs significantly correlated with age \((r > 0.42, p < 0.0001)\) and \(n-3/n-6 (r > 0.60, p < 0.0001)\) (Supplementary Table I a, www.ijch.fi).

Positive correlations among PFAA levels with both age and seafood intake were also observed for both genders. In general, the correlations found in female Inuit were higher than those in male Inuit, while the correlations

---

**Fig. 2.** Serum levels of PFAAs and legacy POPs of Greenlandic Inuit. A) \(\Sigma\)PFSAs (PFOS + PFHxS + PFOSA); B) \(\Sigma\)PFCA (PFHpA + PFOA + PFNA + PFDA + PFUnA + PFDoA + PFTrA); C) \(\Sigma\) legacy POPs (\(\Sigma\)PCBs + \(\Sigma\)pesticides). P-values were adjusted for age and \(n-3/n-6\).
between age, n-3/n-6 and legacy POPs between genders were similar (Supplementary Table I b, www.ijch.fi). For male Inuit, the correlation between n-3/n-6 and PFAAs was weaker than that between legacy POPs and n-3/n-6 (Supplementary Table I b, www.ijch.fi).

**Correlation between PFAAs and legacy POPs**

To explore whether the sources for the body burden of PFAAs and legacy POPs in Greenlandic Inuit were identical, we analysed the correlation between serum PFAAs and legacy POPs. For the Nuuk Inuit, positive correlations between serum PFOS, PFSA, PFCAs and legacy POPs were observed. But after adjustment for age and seafood intake (n-3/n-6), the significant correlations of PFOS and PFSA with legacy POPs disappeared (Table III). For the non-Nuuk Inuit, significant correlations between serum PFAAs and legacy POPs were observed both before and after adjustments for age and n-3/n-6 (Table III). The correlation between PFAAs and legacy POPs was also different between genders. For the male Nuuk Inuit no correlations were observed, possibly because of the low number of males in the study (n = 5). For non-Nuuk males the significant correlation between PFAAs and legacy POPs disappeared after adjustment for age and n-3/n-6. For non-Nuuk female Inuit and for female Inuit in general, serum PFAAs significantly correlated to legacy POPs both before and after adjustment for age and n-3/n-6, whereas for Nuuk females alone the significance disappeared upon adjustment (Table III).

**Time trend of serum PFAAs levels for Nuuk Inuit**

Temporal trend analysis was performed for the district of Nuuk, where a sufficient number of samples were available for the period 1998–2005. As shown in Table IV, PFOS level and PFCA level showed 2.2% and 7.1% yearly increasing trends, respectively, for female Inuit. For the pooled gender data, 28%, 28%, 10%, 13% and 13% yearly increasing trends, respectively, were observed.

### Table III: Association between serum PFCs and serum legacy POPs

| Gender | District | PFOS | PFOA | ΣPFSA | ΣPFCa |
|--------|----------|------|------|-------|-------|
|        |          | raw  | adjusted | raw  | adjusted | raw  | adjusted | raw  | adjusted |
| Male   | Nuuk     | 131  | 131 | 131  | 131 | 131  | 131 | 131  | 131  |
|        | non-Nuuk | 131  | 125 | 131  | 125 | 131  | 125 | 131  | 125  |
|        |          | β<sub>Legacy POPs</sub> | 0.39 | 0.32 | 0.03 | 0.09 | 0.38 | 0.31 | 0.45 | 0.32 |
|        |          | p     | 0.004 | 0.08 | 0.82 | 0.54 | 0.005 | 0.08 | 0.0001 | 0.04 |
| Female | Nuuk     | 262  | 256 | 262  | 256 | 262  | 256 | 262  | 256  |
|        | non-Nuuk | 262  | 256 | 262  | 256 | 262  | 256 | 262  | 256  |
|        |          | β<sub>Legacy POPs</sub> | 0.54 | 0.38 | 0.28 | 0.09 | 0.52 | 0.36 | 0.45 | 0.16 |
|        |          | P     | <0.0001 | <0.0001 | 0.01 | 0.001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Male   | Nuuk     | 68   | 63  | 68   | 63  | 68   | 63  | 68   | 63   |
|        | non-Nuuk | 68   | 63  | 68   | 63  | 68   | 63  | 68   | 63   |
|        |          | β<sub>Legacy POPs</sub> | 0.33 | 0.27 | 0.08 | 0.04 | 0.32 | 0.27 | 0.27 | 0.11 |
|        |          | p     | 0.002 | ns | ns | ns | ns | ns | ns |
| Female | Nuuk     | 73   | 68  | 73   | 68  | 73   | 68  | 73   | 68   |
|        | non-Nuuk | 73   | 68  | 73   | 68  | 73   | 68  | 73   | 68   |
|        |          | β<sub>Legacy POPs</sub> | 0.37 | 0.13 | 0.30 | 0.19 | 0.35 | 0.14 | 0.27 | 0.03 |
|        |          | P     | 0.002 | ns | ns | ns | ns | ns | ns |
| Male   | Nuuk     | 126  | 126 | 126  | 126 | 126  | 126 | 126  | 126  |
|        | non-Nuuk | 126  | 126 | 126  | 126 | 126  | 126 | 126  | 126  |
|        |          | β<sub>Legacy POPs</sub> | 0.38 | 0.31 | 0.01 | 0.07 | 0.36 | 0.30 | 0.42 | 0.30 |
|        |          | p     | 0.007 | ns | ns | ns | 0.009 | ns | <0.0001 | 0.05 |
| Female | Nuuk     | 62   | 62  | 62   | 62  | 62   | 62  | 62   | 62   |
|        | non-Nuuk | 62   | 62  | 62   | 62  | 62   | 62  | 62   | 62   |
|        |          | β<sub>Legacy POPs</sub> | 0.56 | 0.65 | 0.30 | 0.40 | 0.53 | 0.63 | 0.31 | 0.31 |
|        |          | p     | <0.0001 | <0.0001 | 0.001 | 0.001 | <0.0001 | <0.0001 | <0.0001 | 0.002 |
| Male   | Nuuk     | 188  | 188 | 188  | 188 | 188  | 188 | 188  | 188  |
|        | non-Nuuk | 188  | 188 | 188  | 188 | 188  | 188 | 188  | 188  |
|        |          | β<sub>Legacy POPs</sub> | 0.65 | 0.46 | 0.45 | 0.19 | 0.62 | 0.44 | 0.51 | 0.24 |
|        |          | p     | <0.0001 | <0.0001 | 0.001 | ns | <0.0001 | <0.0001 | <0.0001 | 0.009 |

β<sub>Legacy POPs</sub> is the regression coefficient of PFAAs to legacy POPs. Legacy POPs is the summation of PCBs and pesticides (ΣPCBs + ΣPesticides). Adjusted data was adjusted for age and n-3/n-6. ns = not significant (p > 0.05).
For other test PFAAs, no time trend was observed. ns
Time trend analysis was not performed for the male Inuit because there were only 5 males studied in Nuuk.

For the serum level of PFOA and 
appeared (Table IV). No significant time trend was observed after adjustment for age, the significant trend dissap-

15% yearly increasing trends were found for PFNA, PFDA, PFDoA, PFTrA and ΣPFCAs, respectively. The trends were statistically significant (p < 0.05). However, after adjustment for age, the significant trend disappeared (Table IV). No significant time trend was observed for the serum level of PFOA and ΣPFSA before and after adjustment for age (Table IV), and neither for PFHxS, PFOS, PFHpA or PFUnA (data not shown).

**Discussion**

The range observed for serum PFOS and PFOA in all the Greenlandic districts in the present study corresponded to the range observed in European biomonitoring studies of general populations (14) although the PFOA was found slightly lower in Inuit (11,14). The serum PFOS level of Nuuk Inuit were comparable to those observed in Europeans from Sweden and from Northern Bavaria, Germany, while non-Nuuk Inuit had a lower level of PFOS – similar to that of Europeans in Southern Bavaria, Germany, and in Tarragona, Spain (14). The median serum PFOS and PFOA concentrations in male Greenlandic Inuit were lower than the plasma levels of PFOS and PFOA in Danish men (39).

Very few data are available for PFAA serum concentrations from other Arctic locations; the literature data that are available are summarized in Table V. The range of mean concentrations of PFOS and PFOA in the other Arctic studies were 9.3–36.9 ng/ml and 1.0–3.4 ng/ml, respectively, while the mean concentrations of PFOS and PFOA of Green-landic Inuit reported in the present study were 33.3 ng/ml and 2.3 ng/ml, respectively (Table V). The size of our data set is larger than most of the other Arctic data. Moreover, both male and female samples were included in the present study, thus avoiding the bias that could be generated by only including serum samples from one gender. The PFOS mean concentration (33.3 ng/ml) of the Greenlandic Inuit in this study was slightly higher than the value (25.7 ng/ml) reported by Chateau-Degat et al., which also included male and female Inuit (40). PFOS concentrations reported in other Arctic studies including relatively few female subjects were generally lower than the PFOS levels of Greenlandic Inuit observed in the present study (Table V). However, the mean PFOA level of the pooled Greenlandic Inuit in our study was comparable to the other reported Arctic studies (Table V).

We did observe gender differences in PFAA levels; Greenlandic Inuit within the same district tended to be in accordance with the majority of studies on gender dependency of PFOS serum concentrations (14), with higher levels in male donors. This gender difference has been partially explained by increased excretion through menstrual flow (41), transplacental transfer of PFOS and other PFAAs to the developing foetus and transfer via milk during breastfeeding in females of younger ages (42). Other explanations of lower levels in women rely on higher renal clearance of PFAAs in women and longer half-lives in males, based on studies of laboratory rodents (14). But the last assumption might not be completely true, as better renal clearance in females was not observed in other species (dogs, rabbits and mice) (14), and no sex

**Table IV.** Time trend of serum concentrations (ng/ml) of PFAAs in Greenlandic Inuit from Nuuk in the period 1998–2005

|          | Raw | Adjust age |
|----------|-----|------------|
|          | (female only) | (male + female) |
|          | Slope (%) | Slope | Slope |
|          | 95% CI | p-value | 95% CI | p-value | 95% CI | p-value |
| PFOS     | 1.2,3.1 | <0.02 | 9.2 | 0.009 | ns |
| PFOA     | 20,20 | ns | 10 | ns | <0.03 |
| PFNA     | 20,20 | ns | 13 | ns | <0.03 |
| PFDA     | 3.3 | ns | 11.5 | ns | <0.03 |
| PFDoA    | 4.6 | ns | 9.4,28 | ns | <0.03 |
| PFTrA    | 2.1 | ns | 19,15 | ns | <0.03 |
| ΣPFSAs   | 7.1 | ns | 4.5,25 | ns | <0.03 |
| ΣPFCAs   | 2.4 | ns | 15,55 | ns | <0.03 |

Slope: yearly difference; values in bold indicate that the trend is statistically significant.
ΣPFSAs: PFOS + PFHxS + PFOSA; ΣPFCAs: PFHpA + PFOA + PFNA + PFDA + PFUnA + PFDoA + PFTrA.
Time trend analysis was not performed for the male Inuit because there were only 5 males studied in Nuuk.
For other test PFAAs, no time trend was observed. ns = not significant (p > 0.05).
**Table V.** Summary of PFOS and PFOA serum concentrations reported for Arctic populations. Concentrations are given in ng/ml

| Location                                      | Population          | Sampling period | Gender (number of samples) | Mean age (min-max) | PFOS mean concentration (min-max) | PFOA mean concentration (min-max) | Reference                  |
|-----------------------------------------------|---------------------|-----------------|----------------------------|--------------------|-----------------------------------|----------------------------------|-----------------------------|
| Greenland (10 districts)                      | Inuit               | 1997–2006       | Male + Female (284*)       | 46.0 (18.0–73.0)   | 33.3 (1.5–213)                   | 2.3 (0.20–10.8)                  | Present study               |
|                                              |                     |                 | Male (74)                  | 39.0 (18.0–73.0)   | 32.9 (4.0–213)                   | 2.3 (0.20–10.8)                  |                             |
|                                              |                     |                 | Female (209)               | 49.0 (18.0–66.0)   | 33.5 (1.5–172)                   | 2.3 (0.20–7.8)                   |                             |
| Northwest and Nunavut Territories (Canada)   | Female (10 pooled   | 1994–2001       | Female (10 pooled maternal blood) | 36.9 (2.8–57.9)   | 2.20 (0.5–172)                    | 2.20 (0.5–5.5)                   | Tittlemier et al. (27)      |
| Nunavik (Canada)                              | Inuit               | 2004            | Male + Female (723)        | 36.9 (18.0–74.0)   | 25.7                              | -                               | Chatean-Degat et al. (40)   |
|                                              |                     |                 | Male (325)                 | 36.6                | 28.2                              | -                               |                             |
|                                              |                     |                 | Female (395)               | 37.0                | 23.1                              | -                               |                             |
| Yup’ik (Alaska, USA)                         | Female (180-202)    | 2004–2006       | 26.0                       | 7.40 (<0.2–28.0)   | 1.0 (<0.1–4.3)                   | AMAP (20)                       |
| Bodo (Norway)                                 | Female (12)         | 2004            | 39.0 (29.0–48.0)           | 16.0 (9.0–29.0)    | 2.3 (1.7–7.0)                    | AMAP (20)                       |
| Kiruna (Sweden)                               | Female (25)         | 2006            | 27.0 (22.0–33.0)           | 8.10 (1.2–22.0)    | 1.6 (<LOD–3.6)                   | AMAP (20)                       |
| Taimyr (Russia)                               | Female (12)         | 2002            | 26.0 (20.0–35.0)           | 9.30 (5.1–14.0)    | 2.2 (1.2–5.7)                    | AMAP (20)                       |
| Naryan Mar (Russia)                           | Female (12)         | 2002            | 30.0 (22.0–35.0)           | 16.0 (5.0–49.0)    | 1.7 (0.8–5.2)                    | AMAP (20)                       |
| Faroe Islands                                 | Female (12)         | 2000–2001       | pregnant**                 | 25.5 (16.4–38.3)   | 2.6 (0.1–4.0)                    | Weihe et al. (28)               |

*One sample had no gender information.
**Age of the pregnant women was unknown.
difference was found in the renal clearance of humans (41). Moreover, our data do not support the hypothesis that the higher PFAA levels in males were due to a higher intake of traditional marine food, because males and females had similar seafood intake (n-3/n-6). Moreover, after adjustment for age and n-3/n-6, the PFAA differences between genders were still statistically significant. We suggest that other sources must contribute to the higher levels of PFAs in male Greenlandic Inuit.

Since PFAs are very persistent, the body burden of PFAs may increase with age. Studies investigating the dependency of PFAs serum concentrations on age have given inconsistent results, with some studies reporting statistically significant correlations (17,36), and others not observing any correlations (16,43). In this study, no correlation was observed between PFAs and age for Nuuk Inuit, while significant correlation was found for non-Nuuk Inuit. Because the median age of non-Nuuk Inuit was lower than that of Nuuk Inuit in this study, this discrepancy may be related to the fact that the lifestyle of younger individuals could pose a higher chance of exposure to PFAs (via clothing or consumption of food items that have been in close contact with packaging containing PFCs) (26,44).

Dallaire et al. also observed an age dependency of PFOS plasma concentrations, with older individuals having higher concentrations (26). This was partially explained by the fact that marine food intake also increases with age. Consumption of traditional food has been suggested to be an important source of PFAS exposure for Indigenous Arctic populations (28,45). Dallaire et al. indicated that consumption of fish and marine mammals, male gender and age were the strongest predictors of PFOS plasma concentrations in the investigated Inuit population. However, diet, gender and age could account for only 28% of the variation in PFOS concentrations (26). In the present study, we observed that the correlation between PFAs and seafood intake was weaker than the correlation between legacy POPs and seafood intake, suggesting that seafood intake might be the main source for legacy POPs and to a lesser degree for PFAs. Thus other factors may contribute to PFAs exposure in the Inuit populations, such as consumer products (e.g., impregnation spray for outdoor clothing) and different indoor sources (e.g., house dust in carpeted houses). Moreover, our data are supported by the study of Tittlemier and co-workers, which suggested that a diet based on traditional foods does not contribute to higher body burdens of PFAS to the same degree as has been observed for legacy POPs (27).

Similarly to the data reported by Fromme and co-workers (36), the correlation between PFAs and marine food intake observed for male Inuit in the present study was weaker than that observed for female Inuit, suggesting that sources other than n-3/n-6 might also contribute to the higher PFAA levels in male Inuit. Moderately positive correlations were observed between legacy POPs and age as well as n-3/n-6, similar to previous reports (21,35,46). In male Inuit, the correlation between legacy POPs and n-3/n-6 was stronger than the correlation between PFAs and n-3/n-6, further suggesting that other sources might play a more important role than seafood intake in the higher body levels of PFAs in Greenlandic male Inuit as observed in the present study.

The correlation between PFAs and legacy POPs differed between districts. For Nuuk Inuit, no significant association was observed between PFAs and legacy POPs, suggesting that sources of serum PFAs and legacy POPs in Nuuk Inuit might vary. For non-Nuuk Inuit, significant correlations between serum PFAs and legacy POPs were observed both before and after adjustments for age and n-3/n-6, suggesting that there might be common sources for the body burden of PFAs and legacy POPs in non-Nuuk Inuit. The correlation between PFAs and legacy POPs was also different between genders; no correlation was found for male Inuit and a significant correlation was observed for females, further suggesting that sources other than seafood intake played an important role in the body burden of PFAs and legacy POPs for male Greenlandic Inuit.

Overall, our data indicate that the sources contributing to the body burden of PFAs and legacy POPs might be different for Nuuk Inuit when compared to non-Nuuk Inuit. These sources seem to be something other than seafood intake. Further studies are needed to clarify the PFAs and legacy POP exposure routes of Greenlandic Inuit.

For female Nuuk Inuit, we observed an age-dependent, increasing trend of PFOS and ΣPFCAs. We also observed increasing, age-dependent trends for PFNA, PFDA, PFDoA and PFTrA in all Nuuk Inuit during the period between 1998 and 2005. However, we cannot conclude that there was an increasing trend of PFAs in Nuuk Inuit during 1998–2005, since the significant trend disappeared upon adjustment forage and only 4 years of data series were used in the present study. However, neither did we observe an obvious decreasing trend for PFAs in Nuuk Inuit. Further research including more time series is needed to study the time trend of PFAs in Greenlandic Inuit.

In conclusion, the levels of PFOS and PFOA of Greenlandic Inuit were comparable to those found in European populations and were similar to, or slightly higher than, those of other Arctic populations. The PFAs serum levels differed between the 2 district groups, with higher levels found in the Nuuk district than the pooled non-Nuuk districts. Within the districts, higher PFAS levels were found for males. Sources for the body burden of PFAs and legacy POPs in Greenlandic Inuit.
might differ and sources other than seafood intake should be taken into consideration when assessing the body levels of PFAAs in Greenlandic Inuit, especially for male Inuit. An age-dependent, but no obvious increasing trend of serum PFAAs in Nuuk was observed during 1998–2005.

Acknowledgements

The authors would like to thank to the Commission for Scientific Research in Greenland, the Danish Environmental Protection Agency and the Aarhus University Research Foundation for their economic support. Inga Jensen, Kitty K. Petersen and Fariba Barandazi are acknowledged for their technical assistance in sample preparation and analysis.

Conflict of interest and funding
None to declare

References

1. Kissa E. Fluorinated surfactants and repellents. New York: Marcel Dekker; 2001. p. 165.
2. Houde M, Martin JW, Letcher RJ, Solomon KR, Muir DC. Biological monitoring of polyfluoroalkyl substances: a review. Environ Sci Technol. 2006;40(11):3463–73.
3. Lau C, Antikle C, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluorooalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci. 2007;99(2):366–94.
4. Fuentes S, Vicens P, Colomina MT, Domingo JL. Behavioral effects in adult mice exposed to perfluorooctane sulfonate (PFOS). Toxicology. 2007;242(1–3):123–9.
5. Johansson N, Eriksson P, Viberg H. Neonatal exposure to PFOS and PFOA in mice results in changes in proteins which are important for neuronal growth and synaptogenesis in the developing brain. Toxicol Sci. 2009;108(2):412–8.
6. Steenland K, Fletcher T, Savitz DA Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect 2010;118(8):1100–8.
7. United States Environmental Protection Agency (EPA). 2010/15 PFOA Stewardship Program. United States Environmental Protection Agency; 2006 [cited 2011 Oct 21]. Available from: http://www.epa.gov/oppt/pfoa/pubs/stewardship/pfoastewardship.html.
8. EUROPA. Directive 2006/122/EC of the European Parliament and of the Council of 12 December 2006 amending the 30th time Council Directive 76/769/EEC on the approximation of the laws, regulations and administrative provisions of the Member States relating to restrictions on the marketing and use of certain dangerous substances and preparations (perfluorooctane sulfonates). Official Journal of the European Union 2006/49: L372/32–L372/34 [cited 2006 Dec 27]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:372:0032:0034:en:PDF.
9. Stockholm Convention. Fourth Meeting of the conference of the parties of the Stockholm Convention. Châtelaine: Stockholm Convention; 2008 [cited 2009 May 8]. Available from: http://chm.pops.int/
10. Olsen GW, Mair DC, Church TR, Ellefson ME, Reagen WK, Boyd TM, et al. Decline in perfluorooctanesulfonate and other polyfluorooalkyl chemicals in American Red Cross adult blood donors, 2000–2006. Environ Sci Technol. 2008;42(13):4989–95.
11. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect. 2007;115(11):1677–82.
12. Fei C, McLaughlin JK, Tarone RE, Olsen J. Fetal growth indicators and perfluorinated chemicals: a study in the Danish National Birth Cohort. Am J Epidemiol. 2008;168(1):66–72.
13. Fei C, McLaughlin JK, Lipworth L, Olsen J. Maternal levels of perfluorinated chemicals and subfecundity. Hum Reprod. 2009;24(5):1200–5.
14. Fromme H, Tittlemier SA, Volkel W, Wilhelm M, Tvardella D. Perfluorinated compounds – exposure assessment for the general population in Western countries. Int J Hyg Environ Health. 2009;212(3):239–70.
15. Olsen GW, Butenhoff JL, Zobel LR. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol. 2009;27(3–4):212–30.
16. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and comparisons with NHANES 1999–2000. Environ Health Perspect. 2007;115(11):1596–602.
17. Haug LS, Thomsen C, Becher G. Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. Environ Sci Technol. 2009;43(6):2131–6.
18. Harada K, Kozumi A, Saito N, Inoue K, Yoshinaga T, Date C, et al. Historical and geographical aspects of the increasing perfluorooctanoate and perfluorooctane sulfonate contamination in human serum in Japan. Chemosphere. 2007;66(2):293–301.
19. Jin Y, Saito N, Harada KH, Inoue K, Kozumi A. Historical trends in human serum levels of perfluorooctanoate and perfluorooctane sulfonate in Shenyang, China. Tohoku J Exp Med. 2007;212(1):63–70.
20. AMAP Human health in the Arctic. Oslo: Arctic Monitoring and Assessment Programme (AMAP); 2009. xiv + 256 p. Available from: http://www.amap.no/assessment/scientificbackground.htm.
21. Deutsch B, Pedersen HS, Asmund G, Hansen JC. Contaminants, diet, plasma fatty acids and smoking in Greenland 1999–2005. Sci Total Environ. 2007;372(2–3):486–96.
22. AMAP Human health in the Arctic. Oslo: Arctic Monitoring and Assessment Programme (AMAP); 2002. xiii + 137 p. Available from: http://www.amap.no/documents/index.cfm?dirsub=%22/AMAP%22Assessment%22%20Human%20Health%22/2002%20Human%20Health%20in%20the%20Arctic.
23. Bonefeld-Jorgensen EC. Biomonitoring in Greenland: human biomarkers of exposure and effects – a short review. Rural Remote Health. 2010;10(2):1362.
24. Bossi R, Riget FF, Dietz R. Temporal and spatial trends of perfluorinated compounds in ringed seal (Phoca hispida) from Greenland. Environ Sci Technol. 2005;39(19):7416–22.
25. Dietz R, Bossi R, Riget FF, Sonne C, Born EW. Increasing perfluoroalkyl contaminants in east Greenland polar bears (Ursus maritimus): a new toxic threat to the Arctic bears. Environ Sci Technol. 2008;42(7):2701–7.
26. Dallaire R, Ayotte P, Peregrine D, Déry S, Dumas P, Langlois E, et al. Determinants of plasma concentrations of perfluorooctanesulfonate and brominated organic compounds in Nunavik Inuit adults (Canada). Environ Sci Technol. 2009;43(13):5130–6.
27. Tittlemier S, Ryan JJ, Van Oostdam J. Presence of anionic perfluorinated organic compounds in serum collected from northern Canadian populations. Organohalogen Compounds. 2004;66:4009–14.
28. Weihe P, Kato K, Calafat AM, Nielsen F, Wanigatunga AA, Needham LL, et al. Serum concentrations of polyfluoroalkyl compounds in Faroese whale meat consumers. Environ Sci Technol. 2008;42(16):6291–5.

29. Cote S, Ayotte P, Dodin S, Blanchet C, Mulvad G, Petersen HS, et al. Plasma organochlorine concentrations and bone ultrasound measurements: a cross-sectional study in peri- and postmenopausal Inuit women from Green-land. Environ Health. 2006;5:33.

30. Deutch B, Hansen JC. High human plasma levels of organochlorine compounds in Greenland. Regional differences and lifestyle effects. Dan Med Bull. 2000;47(2):132–7.

31. Bonefeld-Jørgensen EC, Long M. Dioxin-like activity in the blood of Greenlandic Inuit and Danish women: a pilot study. Int J Circumpolar Health. 2010;69(2):181–94.

32. Hansen KJ, Clemen LA, Ellefson ME, Johnson HO. Compound-specific, quantitative characterization of organic fluoro chemicals in biological matrices. Environ Sci Technol. 2001;35(4):766–70.

33. AMAP. AMAP ring test for persistent organic pollutants in human serum 2000–2010. Quebec: Centre de toxicologie, Institut national de santé publique du Québec; 2008 [cited 2008 Jan 7]. Available from: http://www.in-spq.qc.ca/ctq/paqe/amap/rapports.asp.

34. Deutch B, Pedersen HS, Jorgensen EC, Hansen JC. Smoking as a determinant of high organochlorine levels in Greenland. Arch Environ Health. 2003;58(1):30–6.

35. Deutch B, Pedersen HS, Hansen JC. Dietary composition in Greenland 2000, plasma fatty acids and persistent organic pollutants. Sci Total Environ. 2004;331(1–3):177–88.

36. Fromme H, Midasch O, Twardella D, Angerer J, Boehmer S, Liebl B. Occurrence of perfluorinated substances in an adult German population in southern Bavaria. Int Arch Occup Environ Health. 2007;80(4):313–9.

37. Nicholson MD, Fryer RJ, Larsen RJ. robust method for analysing contaminant trend monitoring data. Techniques in marine environmental sciences. Copenhagen: International Council for the Exploration of the Sea (ICES); 1998. p. 22.

38. Bignert A. PIA statistical tool for analysing AMAP time trend datasets. Distribution package (v.1.0). AMAP Documents Database; 2007 [cited 2007 June 5]. Available from: http://amap.no/documents/index.cfm?dirsub=%2FPIA%20Trend%20Analysis%20Package&sort=default.

39. Eriksen KT, Sorensen M, McLaughlin JK, Tjonneland A, Overvad K, Raaschou-Nielsen O. Determinants of plasma PFOA and PFOS levels among 652 Danish men (dagger). Environ Sci Technol. 2011;45(19):8137–43.

40. Chateau-Degat ML, Perez D, Dallaire R, Ayotte P, Dery S, Dewailly E. Effects of perfluorooctanesulfonate exposure on plasma lipid levels in the Inuit population of Nunavik (Northern Quebec). Environ Res. 2010;110(7):710–7.

41. Harada K, Inoue K, Morikawa A, Yoshinaga T, Saito N, Koizumi A. Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their speciesspecific excretion. Environ Res. 2005;99(2):253–61.

42. Fei C, McLaughlin JK, Lipworth L, Olsen J. Maternal concentrations of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) and duration of breastfeeding. Scand J Work Environ Health. 2010;36(5):413–21.

43. Kannan K, Corsolini S, Falandysz J, Fillmann G, Kumar KS, Loganathan BG, et al. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol. 2004;38(17):4489–95.

44. Begley TH, Hsu W, Noonan G, Diachenko G. Migration of fluorochemical paper additives from food-contact paper into foods and food simulants. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008;25(3):384–90.

45. Ostertag SK, Tague BA, Humphries MM, Tittlemier SA Chan HM. Estimated dietary exposure to fluorinated compounds from traditional foods among Inuit in Nunavut, Canada. Chemosphere. 2009;75(9):1165–72.

46. Deutch B, Dyerberg J, Pedersen HS, Asmund G, Moller P, Hansen JC. Dietary composition and contaminants in north Greenland, in the 1970sand 2004. Sci Total Environ. 2006;370(2–3):372–81.

*Eva C. Bonefeld-Jørgensen
Aarhus University, School of Public Health
Centre of Arctic Environmental Medicine
Bartholins Allé 2
8000 Aarhus
DENMARK
Email: ebj@mil.au.dk